Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07544368

Mediterranean Diet and Oxidative Stress in Type 1 Diabetes (MEDOX-T1D)

Achieving optimal glycemic control in type 1 diabetes requires a holistic approach that includes individualized medical nutrition therapy in addition to appropriate insulin therapy. When diabetes is poorly managed, metabolic control is impaired. Hyperglycemic events increase oxidative stress in the body and can lead to complications. The aim of this study is to examine the effect of a 12-week Mediterranean diet on oxidative stress markers in children with type 1 diabetes who do not meet the metabolic target (HbA1c > 7%) and whose adherence to the Mediterranean diet is "poor" and "needs improvement".

The study, planned between March 2026 and March 2027, will be conducted with girls aged 10-18 years with type 1 diabetes who are followed up at the Department of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University. In the first phase, participants were divided into groups based on their HbA1c levels: those with HbA1c ≤ 7 met the metabolic target (Group A); Those with HbA1c > 7 will be divided into two groups: those not meeting the metabolic target (Group B). In the second stage, the intervention group will be determined according to the results of the KIDMED, the pediatric Mediterranean diet adherence scale. Those in Group B who did not meet the metabolic targets and those with "poor" and "need improvement" KIDMED results will form the intervention group (Group C). Adolescents in Group C will receive a 12-week Mediterranean diet intervention. Information will be collected from participants using questionnaires, scales, and experimental methods. This includes completing the 'Personal Information Form', 'Biochemical Parameters Form', '3-Day Nutrition Questionnaire', 'KIDMED scale', and 'Sensor Data Form'. The obtained data will be analyzed both individually and before-and-after using SPSS 26.

The findings are expected to show improvement in OS markers in the intervention group. Improvement in glycemic control markers is also predicted. A decrease in HbA1c levels, a reduction in blood sugar fluctuations, and an increase in the duration of staying within the target range are expected.

This study is expected to contribute to the literature by revealing the effects of the Mediterranean diet on oxidative stress and metabolic control parameters in type 1 diabetes. It is anticipated that the findings will support the potential role of dietary approaches with antioxidant properties not only in glycemic control but also in oxidative stress levels and long-term complication risks.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Type 1 diabetes is an autoimmune disease that primarily occurs in childhood and is characterized by insufficient insulin secretion due to damage to the beta cells of the pancreas. While the incidence of Type 1 diabetes is increasing, the age of onset is also decreasing.

Diabetes management is crucial for maintaining and protecting health. When glycemic control is not achieved, the number of hypoglycemic and hyperglycemic events increases. HbA1c levels rise. This situation results in poor metabolic control. Oxidative stress in the body increases. Oxidative stress can play a role in the pathogenesis of diabetes, and if the disease is not controlled, it leads to the development and rapid progression of complications (retinopathy, nephropathy, neuropathy, etc.).

Many studies conducted on diabetic children have shown that their oxidative stress levels are high and antioxidant levels are low compared to healthy controls.

Nutrition, the foods we consume, are modifiable determinants of oxidative stress. The antioxidant and polyphenol content of the diet is particularly important. The Mediterranean diet; Foods rich in antioxidants, such as vegetables, fruits, legumes, fish, olive oil, nuts, and fermented foods, have been shown in many studies to have a protective effect.

In the first phase of the study, participants will be divided into two groups based on their HbA1c levels: those with HbA1c ≤7 (meeting the metabolic target) (Group A); and those with HbA1c >7 (not meeting the metabolic target) (Group B). Information will be collected from participants using questionnaires, scales, and experimental methods. This includes completing a Personal Information Form, a Biochemical Parameters Form, a 3-Day Food Intake Record, the KIDMED scale, and a continuous glucose monitoring sensor data form. Disease-specific information will be obtained from patient files, while biochemical data will include routine follow-up measurements such as complete blood count, CRP, CK, HbA1c%, lipid profile (HDL, LDL, total cholesterol, triglycerides), liver function tests (AST, ALT), kidney function tests (BUN, urea, creatinine), TSH, ST4, and vitamin D. Oxidative stress markers FASN, G6PD, GST, GR, and 6-PGD will be measured in venous blood. Blood samples will be taken in the outpatient clinic by a diabetes nurse. Anthropometric measurements will be taken as part of the personal information form. Body weight and height measurements will be taken in the outpatient clinic by a nutritionist (the same person). Height measurements will be taken with a stadiometer with 0.1 cm accuracy, while the patient is in an upright position with the head in the Frankfort plane (the ear canal and the lower boundary of the orbit/eye socket are aligned, and the gaze is parallel to the ground). Body weight measurements will be taken with a scale with 0.1 gram accuracy. Anthropometric data (body mass index, weight, height, and standard deviation scores) will be evaluated according to the standards developed by Neyzi et al. for Turkish children. To ensure accurate food consumption records, the nutritionist will provide training on correctly expressing portion sizes using spoons, bowls, ladles, cups, etc., and the patients will be asked to keep a record using a form for 2 weekdays and 1 weekend. In the evaluation of three-day food consumption, the Nutrition Information System (BEBIS) software package containing food compositions specific to Turkey will be used, and the analysis results will be compared with the dietary reference intakes in the recommendations of the Turkish Nutrition Guide.

In the second stage, the intervention group will be determined according to the results of the KIDMED (Mediterranean Diet Quality) scale, which is a pediatric Mediterranean diet adherence scale. The KIDMED scale (Mediterranean Diet Quality) was developed by Serra Majem et al. in 2004. The Turkish validity and reliability study of the scale was conducted by Şahingöz et al. in 2019. The scale consists of 16 questions. The questions are answered with yes (1) and no (2). Items 6, 12, 14, and 16 are scored as -1, and the remaining 12 items are scored as +1. In the evaluation of the scale, ≤ 3 is considered low adherence, 4-7 is considered moderate adherence, and ≥ 8 is considered high adherence. In our study, those in Group B who did not meet metabolic targets, and those with KIDMED results deemed "poor" and "needing improvement," will form the intervention group (Group C).

Adolescents in Group C will be scheduled for a 12-week Mediterranean diet intervention. The Mediterranean Diet training is planned as a 30-45 minute face-to-face meeting, and the brochure to be used in the training is available in Appendix 1. Visits will be made by phone between weeks 2-3 and weeks 7-9, and diet compliance will be monitored with dietitian consultations, with additional motivational consultations provided if necessary. A face-to-face meeting will be held in week 12, and anthropometric measurements will be repeated. Three-day food consumption records will be taken. Biochemical data obtained during routine 3-month follow-up will be retrieved from file information. Oxidative stress markers will be repeated.

If there are cases in Group A that are poor or needing improvement, these individuals will also receive Mediterranean Diet training, and their follow-up will continue with the dietitian of the department they are being monitored by. Participants in group B who received a 'good' KIDMED score will continue with standard medical nutritional therapy under the guidance of a dietitian.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 10-18 years
  • BMI between the 5th and 95th percentile (normal to overweight)
  • Diagnosis of Type 1 Diabetes for ≥1.5 years
  • Users of a continuous glucose monitoring (CGM) system
  • No other comorbidities and not taking medications
  • Non-smokers and non-alcohol users (including e-cigarettes)
  • Written informed consent provided by the participant and their parent/guardian

Exclusion criteria

  • Presence of any acute or chronic disease other than Type 1 Diabetes
  • Current use of any medications
  • BMI ≥ 95th percentile (obese)
  • Presence of an eating disorder
  • Use of tobacco, e-cigarettes, or alcohol

Treatment and study plan

Mediterranean Diet Intervention

Behavioral

Participants will follow a Mediterranean diet rich in plant-based foods, olive oil as the main fat source, moderate consumption of fish and dairy products, and limited intake of red and processed meats. Dietary adherence will be assessed using food records, and participants will be monitored throughout the study period to ensure compliance.

Primary outcomes

  1. HbA1c

    Time frame: 12 weeks compared to baseline

    HbA1c

  2. Mediterranean Diet Quality (KIDMED) Scale

    Time frame: 12 weeks compared to baseline

    Mediterranean Diet Quality (KIDMED) Score: Accordingly, the scores derived from the checklist are classified into three categories: low adherence (≤3), moderate adherence (4-7), and high adherence (≥8).

  3. 6-PGD

    Time frame: 12 weeks compared to baseline

    6-phosphogluconate dehydrogenase

  4. GR

    Time frame: 12 weeks compared to baseline

    U/L, glutathione reductase

  5. GST

    Time frame: 12 weeks compared to baseline

    glutathione S-transferase

  6. G6PD

    Time frame: 12 weeks compared to baseline

    glucose-6-phosphate dehydrogenase

  7. FASN

    Time frame: 12 weeks compared to baseline

    ng/mL, fatty acid synthase

Secondary outcomes

  1. Vitamin D

    Time frame: 12 weeks compared to baseline

    vitamin D

  2. TSH

    Time frame: 12 weeks compared to baseline

    Thyroid stimulated hormone

  3. ST4

    Time frame: 12 weeks compared to baseline

    serum free thyroxine

  4. CRP

    Time frame: 12 weeks compared to baseline

    mg/L, C-Reactive Protein

  5. CK

    Time frame: 12 weeks compared to baseline

    U/L, Creatine Kinase

  6. Total Cholesterol

    Time frame: 12 weeks compared to baseline

    Serum Total Cholesterol

  7. LDL-C

    Time frame: 12 weeks compared to baseline

    mg/dl, LDL cholesterol

  8. HDL-C

    Time frame: 12 weeks compared to baseline

    mg/dl, HDL cholesterol

  9. Triglycerides

    Time frame: 12 weeks compared to baseline

    mg/dL

  10. ALT

    Time frame: 12 weeks compared to baseline

    U/L, Alanine Aminotransferase

  11. AST

    Time frame: 12 weeks compared to baseline

    U/L, Aspartate Aminotransferase

  12. BUN

    Time frame: 12 weeks compared to baseline

    mg/dL, Blood Urea Nitrogen

  13. Creatinine

    Time frame: 12 weeks compared to baseline

    mg/dL

  14. Fasting Plasma Glucose

    Time frame: 12 weeks compared to baseline

    FPG mg/dl

  15. Weight

    Time frame: 12 weeks compared to baseline

    Body weight, kg

  16. Body Mass Index

    Time frame: 12 weeks compared to baseline

    BMI kg/m2

  17. Carbohydrate

    Time frame: 12 weeks compared to baseline

    Carbohydrate intake, gram

  18. Carbohydrate

    Time frame: 12 weeks compared to baseline

    Carbohydrate intake, %

  19. Protein

    Time frame: 12 weeks compared to baseline

    Protein intake, gram

  20. Protein

    Time frame: 12 weeks compared to baseline

    Protein intake, %

  21. Fat

    Time frame: 12 weeks compared to baseline

    Fat intake, gram

  22. Fat

    Time frame: 12 weeks compared to baseline

    Fat intake, %

  23. Energy

    Time frame: 12 weeks compared to baseline

    Energy intake, kcal

  24. Dietary Fiber

    Time frame: 12 weeks compared to baseline

    Dietary Fiber intake, gram

  25. TIR

    Time frame: 12 weeks compared to baseline

    Time in Range (%70-180 mg/dL), CGM metric

  26. TAR

    Time frame: 12 weeks compared to baseline

    Time Above Range (%181-250), CGM metric

  27. TAR

    Time frame: 12 weeks compared to baseline

    Time Above Range (% >250 mg/dL), CGM metric

  28. TBR

    Time frame: 12 weeks compared to baseline

    Time Below Range (%54-69 mg/dL), CGM metric

  29. TBR

    Time frame: 12 weeks compared to baseline

    Time Below Range (%<54 mg/dL), CGM metric

  30. CV

    Time frame: 12 weeks compared to baseline

    Coefficient of Variation (%), CGM metric

  31. SD

    Time frame: 12 weeks compared to baseline

    Standard Deviation (mg/dL), CGM metric

  32. Mean Glucose Levels

    Time frame: 12 weeks compared to baseline

    mg/dL, CGM metric

  33. GMI

    Time frame: 12 weeks compared to baseline

    Glucose Management Indicator (%), CGM metric

  34. Nighttime TIR

    Time frame: 12 weeks compared to baseline

    Nighttime Time in Range (%), CGM metric

  35. Dietary Cholesterol

    Time frame: 12 weeks compared to baseline

    Dietary Cholesterol intake, mg

  36. Vitamin A

    Time frame: 12 weeks compared to baseline

    Vitamin A intake, µg

  37. Vitamin E

    Time frame: 12 weeks compared to baseline

    Vitamin E inatke, mg

  38. Vitamin B1

    Time frame: 12 weeks compared to baseline

    Vitamin B1 intake, mg

  39. Vitamin B2

    Time frame: 12 weeks compared to baseline

    Vitamin B2 intake, mg

  40. Vitamin B3

    Time frame: 12 weeks compared to baseline

    Vitamin B3 intake, mg

  41. Vitamin B5

    Time frame: 12 weeks compared to baseline

    Vitami B5 intake, mg

  42. Vitamin B6

    Time frame: 12 weeks compared to baseline

    Vitamin B6 intake, mg

  43. Vitamin B12

    Time frame: 12 weeks compared to baseline

    Vitamin B12 intake, µg

  44. Folate

    Time frame: 12 weeks compared to baseline

    Folate intake, µg

  45. Vitamin C

    Time frame: 12 weeks compared to baseline

    Vitamin C intake, mg

  46. Calcium

    Time frame: 12 weeks compared to baseline

    Calcium İntake, mg

  47. Magnesium

    Time frame: 12 weeks compared to baseline

    Magnesium intake,mg

  48. Potassium

    Time frame: 12 weeks compared to baseline

    Potassium intake, mg

  49. Phosphorus

    Time frame: 12 weeks compared to baseline

    Phosphorus intake, mg

  50. Iron (Fe)

    Time frame: 12 weeks compared to baseline

    Iron intake, mg

  51. Zinc

    Time frame: 12 weeks compared to baseline

    Zinc intake, mg

  52. Height

    Time frame: 12 weeks compared to baseline

    Body Height, cm

Study contacts

Contact information is provided by the study sponsor or research team.

Beyza Eliuz Tipici

CONTACT

[email protected]

+90 554 624 57 68

Sponsors and collaborators

Lead sponsor

Istanbul University

Other

Registry information

Official study title

The Relationship Between Adherence to the Mediterranean Diet and Oxidative Stress in Children With Type 1 Diabetes

Acronym: MEDOX-T1D

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Apr 22, 2026
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.